2025
Evaluating clinical and pathologic predictors for pathologic lymph node positivity (pN+) in patients with clinical T1-4N0M0 bladder cancer undergoing cystectomy.
Jaime-Casas S, Barragan-Carrillo R, Zugman M, Zang P, Ebrahimi H, Castro D, Mercier B, Li X, Dizman N, Salgia N, Hsu J, Nguyen C, Yip W, Chehrazi-Raffle A, Zengin Z, Meza L, Pal S, Tripathi A. Evaluating clinical and pathologic predictors for pathologic lymph node positivity (pN+) in patients with clinical T1-4N0M0 bladder cancer undergoing cystectomy. Journal Of Clinical Oncology 2025, 43: 877-877. DOI: 10.1200/jco.2025.43.5_suppl.877.Peer-Reviewed Original ResearchConcomitant carcinoma in situRecurrence-free survivalPositive surgical marginsLymph node positivityRadical cystectomyLymphovascular invasionOverall survivalPreoperative hydronephrosisSurgical marginsPathologic predictorsBladder cancerPredictors of lymph node positivityConcomitant CISMultivariate analysisPathologic lymph node positivityPelvic lymph node dissectionPathological lymph node involvementMultivariate Cox proportional hazards modelMultivariate Cox regression modelNode-positiveBladder-preserving approachPreoperative renal functionLymph node dissectionLymph node involvementCarcinoma in situ
2024
Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma
Su D, Schoenfeld D, Ibrahim W, Cabrejo R, Djureinovic D, Baumann R, Rimm D, Khan S, Halaban R, Kluger H, Olino K, Galan A, Clune J. Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma. Journal For ImmunoTherapy Of Cancer 2024, 12: e008646. PMID: 38519058, PMCID: PMC10961546, DOI: 10.1136/jitc-2023-008646.Peer-Reviewed Original ResearchConceptsCTLA-4 expression levelsCancer-associated fibroblastsAssociated with worse survivalExpression of immune checkpointsLAG-3 expressionDesmoplastic melanomaLymphoid aggregatesCTLA-4PD-1Immune checkpointsIntratumoral leukocytesLAG-3Tumor compartmentsWorse survivalCD20+B cellsIncreased expression of immune checkpointsProgrammed cell death protein 1Macrophage/monocyte markerSentinel lymph node positivityCell death protein 1Associated with poor prognosisLymph node positivityDense fibrous stromaPotential prognostic significanceCore of tumors
2023
Predictive accuracy of elevated mitotic rate on lymph node positivity and recurrence in thin melanomas
Ly C, Blaha O, Wei W, Galan A, Kluger H, Ariyan S, Olino K, Clune J. Predictive accuracy of elevated mitotic rate on lymph node positivity and recurrence in thin melanomas. Frontiers In Oncology 2023, 12: 1077226. PMID: 36686728, PMCID: PMC9853390, DOI: 10.3389/fonc.2022.1077226.Peer-Reviewed Original ResearchMelanoma-specific mortalityElevated mitotic rateLymph node positivityMitoses/Mitotic rateT2 tumorsNode positivityThin melanomasSentinel lymph node positivityImportant prognostic factorSingle academic centerPrimary cutaneous melanomaLow mitotic ratePositive SLNNon-ulcerated lesionsSLN biopsyT4 tumorsPatient demographicsPrognostic factorsSLN positivityRetrospective reviewTumor characteristicsBreslow thicknessCutaneous melanomaT category
2022
Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder
Rahman S, Lokeshwar S, Syed J, Javier-Desloges J, Press B, Choksi A, Rajwa P, Pradere B, Ploussard G, Kim J, Monaghan T, Renzulli J, Shariat S, Leapman M. Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder. Urologic Oncology Seminars And Original Investigations 2022, 41: 107.e1-107.e8. PMID: 36481253, DOI: 10.1016/j.urolonc.2022.09.008.Peer-Reviewed Original ResearchConceptsVariant urothelial carcinomaNeoadjuvant chemotherapySubset of patientsUrothelial carcinomaOverall survivalPathologic responseRadical cystectomyNAC useClinical stage II diseaseHospital-based registry studyNeoadjuvant platinum-based chemotherapyPathologic lymph node positivityCox proportional hazards modelNational Cancer DatabaseStage II diseaseLymph node positivityPathologic complete responsePlatinum-based chemotherapyKaplan-Meier analysisMultivariable logistic regressionAnalysis of patientsBladder urothelial carcinomaProportional hazards modelCT2 diseasePathologic upstaging
2016
Neuroendocrine tumors of the pancreas: Degree of cystic component predicts prognosis
Cloyd JM, Kopecky KE, Norton JA, Kunz PL, Fisher GA, Visser BC, Dua MM, Park WG, Poultsides GA. Neuroendocrine tumors of the pancreas: Degree of cystic component predicts prognosis. Surgery 2016, 160: 708-713. PMID: 27216830, DOI: 10.1016/j.surg.2016.04.005.Peer-Reviewed Original ResearchConceptsCystic pancreatic neuroendocrine tumorsPancreatic neuroendocrine tumorsRecurrence-free survivalNeuroendocrine tumorsCystic tumorCystic componentSolid tumorsTumor sizeSingle academic medical centerMost pancreatic neuroendocrine tumorsFavorable clinicopathologic featuresSynchronous liver metastasesLymph node positivityLymph node metastasisTotal tumor sizeHigh gradeCross-sectional imagingAcademic medical centerSynchronous liverImmediate resectionLiver metastasesMetastatic diseaseNode positivityOperative resectionClinicopathologic characteristics
2015
Racial Disparities in Hypofractionated Radiotherapy Breast Cancer Clinical Trials
Housri N, Khan AJ, Taunk N, Goyal S, Nelson CJ, Ferro A, Haffty BG. Racial Disparities in Hypofractionated Radiotherapy Breast Cancer Clinical Trials. The Breast Journal 2015, 21: 387-394. PMID: 25919123, DOI: 10.1111/tbj.12419.Peer-Reviewed Original ResearchConceptsBreast cancer patientsNon-white womenCancer patientsClinical trialsWhite womenRacial disparitiesRadiation oncology clinical trialsBreast cancer clinical trialsRetrospective cohort studyClinico-pathologic factorsLymph node positivityUse of chemotherapyClinical trial enrollmentOncology clinical trialsUse of brachytherapyBreast radiotherapy trialsCancer clinical trialsPaucity of dataCohort studyNode positivityPatient demographicsReceptor statusTrial enrollmentTumor characteristicsDisease stage
2012
Young Patients Undergoing Resection of Pancreatic Cancer Fare Better than their Older Counterparts
He J, Edil BH, Cameron JL, Schulick RD, Hruban RH, Herman JM, Zheng L, Iacobuzio-Donahue C, Ahuja N, Pawlik TM, Wolfgang CL. Young Patients Undergoing Resection of Pancreatic Cancer Fare Better than their Older Counterparts. Journal Of Gastrointestinal Surgery 2012, 17: 339-344. PMID: 23184271, PMCID: PMC3600849, DOI: 10.1007/s11605-012-2066-4.Peer-Reviewed Original ResearchConceptsCharlson-Age Comorbidity IndexOlder age groupsDate of surgeryYounger patientsOlder patientsAge groupsMedian agePDAC patientsPancreatic ductal adenocarcinoma patientsPatients Undergoing ResectionMedian overall survivalResectable pancreatic cancerLymph node positivityYoung patient cohortDuctal adenocarcinoma patientsYounger age groupsCurative resectionUndergoing resectionAbdominal painDistal pancreatectomyR0 resectionTotal pancreatectomyUnderwent pancreaticoduodenectomyElderly patientsNode positivityCan primary tumor markers of cancer-initiating cells predict lymph node positivity in breast cancer patients?
Chagpar A, Neumeister V, Lannin D, Rimm D. Can primary tumor markers of cancer-initiating cells predict lymph node positivity in breast cancer patients? Journal Of Clinical Oncology 2012, 30: 1121-1121. DOI: 10.1200/jco.2012.30.15_suppl.1121.Peer-Reviewed Original ResearchBreast cancer patientsLN statusCancer patientsLymphovascular invasionTumor sizeTumor markersPositive LNsPoor prognosisMedian numberPrimary tumor markersMedian patient ageMedian tumor sizeLymph node positivityLN-positive patientsLymph node statusOnly factorCancer initiating cellsCancer-initiating cellsLevels of CD44Axillary surgeryLN positivityNode positivityPatient agePositive patientsClinicopathologic data
2011
Selective Application of Routine Preoperative Axillary Ultrasonography Reduces Costs for Invasive Breast Cancers
Turaga K, Chau A, Eatrides J, Kiluk J, Khakpour N, Laronga C, Lee M. Selective Application of Routine Preoperative Axillary Ultrasonography Reduces Costs for Invasive Breast Cancers. The Oncologist 2011, 16: 942-948. PMID: 21572122, PMCID: PMC3228129, DOI: 10.1634/theoncologist.2010-0373.Peer-Reviewed Original ResearchConceptsInvasive breast cancerAxillary ultrasoundBreast cancerAxillary sonographyNodal metastasisSentinel lymph node biopsyPreoperative axillary ultrasoundLymph node biopsyLymph node positivityAxillary ultrasonographyNode biopsyDecision analysis treeDiagnostic modalitiesLow riskBase case estimatePatientsRoutine useHospital chargesCancerMetastasisUltrasoundFNANode-positiveSurgeryTumor
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply